SuperGen Reports 2008 Second Quarter Financi...( prodrug increases its in vivo e...)

prodrug increases its in vivo efficacy due to enhanced drug delivery

and stability," highlighted data indicating that S-110 showed robust

anti-tumor activity in prostate and cisplatin-resistant ovarian

carcinoma xenograft models. Additionally, S-110 restored sensitivity

to cisplatin in the ovarian cancer model. Reduced toxicity was

observed along with an increased half-life compared to decitabine.

-- June 2008: The Company had two abstracts accepted for oral and poster

presentation at the 13th Congress of the European Hematology

Association (EHA) that took place June 12-15, 2008 in Copenhagen,

Denmark. Highlights of the presentations are included below:

-- SGI-1776, an oral PIM kinase inhibitor, causes tumor regression in

acute myologenous leukemia (AML) xenograft models (abstract #744).

In a poster presentation entitled "A potent small molecule PIM

kinase inhibitor with in vivo oral availability and activity in cell

lines from hematological malignancies," Dr. Gregory Berk, SuperGen's

Chief Medical Officer, detailed how scientists used the CLIMB

technology to build a model that allowed for the creation of small

molecule PIM kinase inhibitors. SGI-1776 was identified as an

orally available, potent and selective inhibitor of the PIM kinases.

SGI-1776 induces cell cycle arrest, dose dependent apoptosis and a

reduction in phospho-BAD levels in leukemia and lymphoma cell lines.

Phospho-BAD is a direct substrate for PIM, and may serve as a useful

in vivo biomarker for future clinical trials. Most notably,

SGI-1776 induced significant tumor regression in MOLM-13 (AML) and

MV-4-11 (AML) xenograft models.

-- SGI-1252, the Company's JAK2 kinase inhibitor, inhibits tumor cell

'/>"/>